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a b s t r a c t
Fibroblast growth factor receptor 1 (FGFR1) is known to be activated by homodimerization in the pres-
ence of both the FGF agonist ligand and heparan sulfate glycosaminoglycan. FGFR1 homodimers in turn
trigger a variety of downstream signaling cascades via autophosphorylation of tyrosine residues in the
cytoplasmic domain of FGFR1. By means of Bioluminescence Energy Resonance Transfer (BRET) as a sign
of FGFR1 homodimerization, we evaluated in HEK293T cells the effects of all known FGF agonist ligands
on homodimer formation. A significant correlation between BRET2 signaling and ERK1/2 phosphorylation
was observed, leading to a further characterization of the binding and signaling properties of the FGF sub-
families. FGF agonist ligand-FGFR1 binding interactions appear as the main mechanism for the control of
FGFR1 homodimerization and MAPK signaling which demonstrated a high correlation. The bioinformatic
analysis demonstrates the interface of the two pro-triplets SSS (Ser–Ser–Ser) and YGS (Tyr–Gly–Ser)
located in the extracellular and intracellular domain of the FGFR1. These pro-triplets are postulated par-
ticipate in the FGFR1 homodimerization interface interaction. The findings also reveal that FGF agonist
ligands within the same subfamily of the FGF gene family produced similar increases in FGFR1 homodi-
mer formation and MAPK signaling. Thus, the evolutionary relationship within this gene family appears
to have a distinct functional relevance.
Ó 2011 Elsevier Inc. All rights reserved.
1. Introduction
The FGFR1 plays important roles in several processes of the life
cycle, including cell proliferation, differentiation, and apoptosis [1].
Fibroblast growth factors (FGFs) bind to the extracellular binding
pocket of FGFR1 promoting receptor dimerization and autophos-
phorylation of tyrosine residues in the receptor cytoplasmic do-
main [2]. FGF signaling is strongly regulated at the level of the
extracellular receptor-ligand complex assembly by spatial and
temporal expression of ligands, heparan sulfate proteoglycans,
receptors and also via intracellular modulation of downstream
effectors [3]. However, FGF ligand-FGFR1 binding properties are
the most critical mechanism for the control of FGFR1 signaling.
FGFR1 binds members of the FGF family with different affinities
and capabilities to produce activation, and alternative mRNA splic-
ing leads to isoforms of FGFR1 having special ligand binding prop-
erties [4]. In addition, FGF ligand/FGF ligand and FGFR1/FGFR1
dimerization may expand the spectrum of interactions between
FGFs and FGFR affecting their binding and signaling properties
[5]. Anomalous FGF signaling is associated with several human dis-
eases, for instance uncontrolled FGF signaling has been linked to
the etiology of neurodegenerative disorders, such as major depres-
sive disorder and Parkinson’s disease [6].
In this paper we have studied the agonist-induced rise of FGFR
homodimerization using BRET2 as a sign of FGFR1 binding. We
have evaluated the effects of all known FGF ligands on FGFR1–
FGFR1 homodimer formation by means of BRET2 and significantly
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correlated this action to ERK1/2 phosphorylation leading to a fur-
ther characterization of the binding and signaling properties of
the FGF subfamilies.
2. Materials and methods
2.1. Receptor constructs
The FGFR1 tagged gene was amplified from the pcDNA3.1 +
ÿFGFR1 vector (imaGenes GMBH, Berlin, Germany) using sense
oligonucleotides primer Fw-BglII-FGFR1 (50-GAAGATCTTCCAAAAT
GTCGTAACAACTCCGCC-30) and antisense primer Rv-BamHI-5-
HT1A (50-CGGGATCCCGCCATTGGCAAGCTGG -30) resulting in a
cDNA fragment of 2199 bp, subcloned into the pGFP2-N1
(Perkin–Elmer, Spain) and humanized pRluc-N3 (Packard Bio-
science, Spain). The reading frame and PCR integrity of all cloned
constructs were confirmed by DNA sequencing.
2.2. Cell culture and transfection
HEK293T cells (American Type Culture Collection, USA) were
grown in Dulbecco’s modified Eagle’s medium supplemented with
2 mM L-glutamine, 100 units/ml penicillin/streptomycin, and 10%
(v/v) fetal bovine serum at 37 °C and in an atmosphere of 5% CO2.
For transfection, the cells were plated in six-well dishes at a con-
centration of 1  106 cells/well or in 75 cm2 flasks and cultured
overnight before transfection. The cells were transiently transfec-
ted using linear polyethylenimine reagent (Polysciences Inc., USA).
2.3. BRET2 assay
A BRET2 saturation assay was performed as previously de-
scribed [7]. Briefly, 48 h after transfection, HEK293T cells tran-
siently transfected with constant (1 lg) or increasing amounts
(0.25–9 lg) of plasmids encoding for FGFR1Rluc and FGFR1GFP2,
respectively, were rapidly washed twice in PBS, detached, and
resuspended in the same buffer. For BRET2 measurement, coelen-
terazine-400a, also known as DeepBlue™ C substrate, was added
at a final concentration of 5 lM, and readings with the POLARstar
Optima plate reader (BMG Labtechnologies, Offenburg, Germany).
For concentration–response and kinetic BRET2 experiments,
HEK293T cells were transiently transfected at a constant ratio
(1:2) of FGFR1Rluc/FGFR1GFP2 in presence of heparin (0.5 lM). Cells
were treated with the indicated FGF ligand concentration or vehi-
cle for 2 min before BRET2 measurement. FGF ligand-promoted
BRET2 was calculated by subtracting the BRET2 ratio obtained in
the absence of the FGF ligand from that obtained in the presence
of the FGF ligand. In the case of kinetic measurements, coelenter-
azine-400a was added after the FGF ligand (30 ng/ml), just before
BRET2 measurements. In each experiment, the specificities of
FGFR1/FGFR1 interactions were assessed by comparison with cells
expressing FGFR1GFP2 alone. As another negative control were used
cells individually expressing FGFR1Rluc that were mixed prior to
exposition to coelenterazine-400a with cells individually
expressing FGFR1GFP2.
2.4. ERK1/2 phosphorylation assay
To determine mitogen-activated kinase activity (ERK1/2) in re-
sponse to FGFs, we used the In-cell Western blot as described [8].
Briefly, HEK293T cells transiently expressing FGFR1 were seeded
onto poly-D-lysine-coated 96-well plates (Corning, Corning, NY)
grown to 70% confluence. After 24 h incubation in serum-free med-
ium, cells were treated or not for 2 min with FGF ligands (30 ng/
ml). Cells were washed and fixed with 3.7% paraformaldehyde for
10 min at room temperature, washed, blocked for 90 min in LI-COR
Odyssey Blocking BufferÒ (LI-COR Biosciences, UK) and then incu-
bated overnight at 4 °C with primary monoclonal mouse anti-
phospho-ERK1/2 antibody (Sigma–Aldrich, Stockholm, Sweden)
(diluted 1/10000). Then, cells were washed and incubated with
an infrared secondary antibody (goat anti-mouse, 1:1500, LI-COR
Biosciences, UK) for 1 h in LI-COR Odyssey Blocking BufferÒ at
room temperature, washed and plates were scanned by the Odys-
sey infrared scanner. Total cell number was normalized using
DRAQ5/Sapphire 700 staining agents.
2.5. Bioinformatics prediction of the homodimers interface interaction
Based on a bioinformatics approach, a set of amino acid triplet
homologies have been deduced in receptor homodimers that
may be responsible for receptor–receptor interactions [9,10]. It
has been indicated how such triplets of amino acid residues and
their ‘teams’ may be utilized to construct a kind of code that deter-
mines (and/or predicts) which receptors should or should not form
homodimers. In this study, the FGFR1–FGFR1homodimer has been
analyzed for the existence of a basic set of common triplets in the
two participating receptors that may be responsible for the homo-
dimerization. A comparison with the heavy and light chain of IgG
has also been made where also these triplet are located (see Sup-
plementary Material 1).
Fig. 1. BRET2 studies of FGFR1/FGFR1 homodimer response to FGF ligands in living HEK293T cells. BRET2 was measured at a fixed ratio (1:2) of expression levels of FGFR1Rluc/
FGFR1GFP2 treated with FGF ligands 2 min before BRET2 measurement in presence of heparin (0.5 lM). Results are expressed as normalized BRET2 ratio as described in
Section 2. The agonist-induced rise of the BRET2max value is shown in percent of the vehicle value in absence of FGF agonist ligand. Shaded area represents the 95% confidence
interval of the mean vehicle value. Dashed lines represent 50% of BRET2max signal. Data represent the mean ± SEM of four independent experiments performed each in
triplicate. ⁄, ⁄⁄ and ⁄⁄⁄: Significantly different compared to FGF-2 treatment (P < 0.05, P < 0.01 and P < 0.001, respectively) by one-way ANOVA followed by Dunnett’s
comparison post-test.
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2.6. Statistical analysis
The number of samples (n) in each experimental condition is
indicated in Figure legends. Statistical evaluation of the biochemi-
cal data was performed with one-way analysis of variance
(ANOVA) followed by Dunnett’s comparison post-test or two-way
ANOVA followed by Bonferroni comparison post-test. The P value
0.05 and lower was considered significant. Pearson product–
moment correlation coefficient was use to determine lineal
relation between two quantitative variable (BRET2max signal and
ERK1/2 activity).
3. Results
3.1. Differential increases in formation of FGFR1 homodimer upon FGF
agonist ligand treatment based on the BRET2 technique
The effect of FGF agonist ligand treatment was studied on
FGFR1/FGFR1 homodimer formation by means of BRET2 analysis.
HEK293T cells were transiently co-transfected at a constant ratio
(1:2) of FGFR1Rluc/FGFR1GFP2. As a positive control were used cells
expressing a GFP2-Rluc tandem fusion protein. A mixture of cells
expressing singly FGFRRluc or FGFRGFP2 was used as a negative con-
trol. Cells were treated with the indicated high FGF agonist ligand
concentration (30 ng/ml), expected to produce a maximal activa-
tion of FGFR1 [11], or vehicle for 2 min before BRET2 measure-
ments. A positive BRET2 signal was obtained from the transfer of
energy between FGFRRluc and FGFRGFP2. The FGF agonist ligand
treatment with FGF-1, -2, -4, -5, -6, -8, -9, -19 and -20 led to an in-
crease above 50% of the basal value in the BRET2 signal. With the
exception of FGF-1 the other FGF agonist ligand treatments
showed significantly reduced increases in the BRET2 vs FGF-2
treatment (Fig. 1). The FGF agonist ligand treatment with FGF-16,
-17, -18, -21 and -23 led to a further reduction of the increase in
the BRET2 signal as seen from the modest rise of this signal in
the range of 30–40% (Fig. 1). The remaining FGF agonist ligands
FGF-3, -7, -10, -11, -12, -13, -14 and -22 produced only weak
non-significant increases of the BRET2 values in the order of 10%
(Fig. 1).
3.2. Different potencies and kinetics of FGF agonist ligands in
producing FGFR1/FGFR1 homodimers based on the BRET2 technique
Concentration–response curves with FGF-2, FGF-4, FGF-8, FGF-
9, FGF-10, FGF-19 and FGF-20 were performed on the development
BRET2 signal in HEK293T cells. The cells were transiently co-
transfected at a constant ratio (1:2) of FGFR1Rluc/FGFR1GFP2 and
treated with these FGF agonist ligands as indicated for 2 min
before BRET2 measurement. A representative figure of the results
from FGF agonist ligand treatments is shown (Fig 2A, details in
Supplementary Material 2). As seen in Fig 2A, FGF-2 treatment
showed the highest potency to produce a rise of the BRET2 value.
The other FGF agonist ligands tested shifted the curves of the rise
of BRET2 signal to the right indicating a reduced potency vs
FGF-2 to promote FGFR1 homodimer formation compared to
FGF-2 (Fig. 2A). FGF-8, FGF-9 and FGF-20 significantly increased
the EC50 values (Fig. 2A and Supplementary Material 2). As also
shown in Fig 2A, FGF-10 was unable to promote a rise of the BRET2
signal at low concentrations. At a high concentration of FGF-10 a
weak BRET2 signal developed.
The kinetics of the FGFR1Rluc/FGFR1GFP2 interaction after FGF
agonist treatment was also studied in transiently transfected
HEK293T cells using BRET2 assay over a period of 30 min. As shown
in Fig. 2B, FGF-2 and FGF-4 treatments showed no significant
change of the BRET2 value over the first 10 min. Also FGF-19
although with reduced BRET2max value showed similar results. By
contrast, treatment with FGF-9, -20 and to a lesser extent with
FGF-8 resulted in a rapid reduction of the BRET2 signal with time
(Fig. 2B). A marked reduction of the BRET2 signal took place during
the first 10 min after FGF-9, and FGF-20 treatment which was sig-
nificantly different compared with FGF-2 and FGF-4 treatment.
3.3. Differential increases in ERK1/2 phosphorylation levels after
activation of FGFR1 with FGF agonist ligand treatment
The FGFR1 mediated rise in ERK1/2 phosphorylation levels was
studied upon treatment with the same high concentration of FGF
agonist ligands as in the BRET2 experiments. The findings showed
a marked increase in the ERK1/2 phosphorylation levels (maximal
response shown in% of vehicle) after treatment with FGF-1, -2, -4, -
5, -6, -19, which significantly correlated with our BRET2 results
(Fig. 3 and Supplementary Material 3). A modest rise of ERK1/2
phosphorylation levels was found with FGF-8, -9 and -20 which
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Fig. 2. BRET2 studies of FGFR1Rluc interactions with FGFR1GFP2 in living HEK293T
cells. BRET2 was measured at a fixed ratio (1:2) of expression levels of FGFR1Rluc/
FGFR1GFP2 in presence of heparin (0.5 lM). (A) Concentration–response curves of
the effects of FGFs on FGFR1/FGFR1 homodimer formation. Cells expressing
FGFR1Rluc and FGFR1GFP2 were stimulated in the presence or absence of different
concentrations of the FGF ligands shown. Results are expressed as normalized
BRET2 ratio with the agonist-induced rise of the BRET2max value taken in% of the
value in the absence of FGF ligand as described in Section 2. Data represent the
mean ± SEM of five independent experiments performed each in duplicate. (B)
Kinetics of FGFR1Rluc/FGFR1GFP2 homodimer formation after the addition of the each
FGF agonist ligand at time 0. Similar experiments were carried out on cells without
treatment (vehicle). Mean ± SEM of five independent experiments performed each
in triplicate. The slope value during the first exposure time period (0–10 min) is
ÿ0.25 ± 0.44 for FGF-2 and ÿ0.66 ± 0.19 and ÿ1.39 ± 0.30 for FGF-9 and FGF-20,
respectively. Linearity was observed in the slopes evaluated with R2 = 0.90, 0.80 and
0.70 for FGF-2, -9 and -20 respectively. ⁄⁄⁄: The slopes for FGF-9 and FGF-20 are
significantly different from the one after FGF-2 treatment in the period of 0–10 min
by two-way ANOVA (P < 0001) followed by Bonferroni comparison post-test.
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also correlated with the modest increase in BRET2 levels (Fig. 3).
The other agonist ligands FGF-3, -7, -10, -11, -12, -13, -14 and -
22, did not produce a significant increase in ERK1/2 phosphoryla-
tion levels (Fig. 3) as expected from their failure to produce a rise
of the BRET2 signal (Fig. 1). The findings reveal a convincing and
significant correlation between the rise of the BRET2 signal in re-
sponse to FGF agonist ligands and ERK phosphorylation (Supple-
mentary Material 3).
3.4. Bioinformatic analysis
The results are summary in Supplementary Material 1, shown
that the pro-triplet SSS (Ser–Ser–Ser) is located in both extracellu-
lar immunoglobulin domain as well as in the intracellular juxta-
transmembrane domain. Furthermore, the pro-triple YGS (Tyr–
Gly–Ser) has been demonstrated in the extracellular immunoglob-
ulin domain II. These two pro-triplets were also demonstrated in
the heavy and light variable chain of the IgG and also in the heavy
variable of the IgG M, which also participate in protein–protein
interaction.
4. Discussion
Homodimerization of FGFRs is produced via binding of the FGF
agonist ligand/heparin complex to the extracellular binding pocket
which leads to trans-phosphorylation processes mediating the dif-
ferent FGFR signaling cascades [12,13]. In this paper we have for
the first time studied the extent to which the 23 different types
of FGF agonist ligands produce FGFR1 homodimerization deter-
mined with BRET2 technique and how this property is linked to
an increase in the ERK1/2 phosphorylation levels in the HEK293T
cells. A highly significant correlation was demonstrated between
the FGF agonist ligand induced% rise of the BRET2max value and
the% rise of the maximal ERK1/2 phosphorylation levels (Fig. 4).
Thus, it is likely that the FGFR1 homodimerization is linked at least
to the activation of the MAPK pathway.
Indications has been obtained in Bioinformatic analysis (Sup-
plementary Material 1) that pro-triplets SSS (Ser–Ser–Ser) and
YGS (Tyr–Gly–Ser) may participate as a guide mechanism to help
clasp parts of the homodimer receptor interface at the level of
extracellular domain and in the case of SSS also in the intracellular
domain position [10]. Further analysis will be established if this
hypothesis can be verified.
There are also marked differences among FGF agonist ligands
not only in terms of efficacy to produce FGFR1 homodimerization
as seen from the BRET2max values but also in their potency to
Fig. 3. ERK1/2 of FGFR1 in response to activation by FGF agonist ligands. HEK293T cells transiently expressing FGFR1 were rendered quiescent by serum starvation overnight
prior to ERK1/2 phosphorylation experiments. Subsequently, an additional 2 h pre-incubation step in fresh serum-free medium was performed to minimize basal activity
before the cells were challenged with the FGF agonist ligands. Cells were treated with the indicated FGF agonist ligand or vehicle for 2 min. Phosphorylated-ERK1/2 was
measured using In-Cell Western blot as described in Section 2. The rise of phospho-ERK1/2 levels is expressed as a percent of the vehicle value. Shaded area represents the 95%
confidence interval of the mean vehicle value. Dashed lines represent 50% of the maximal phosphorylated-ERK1/2 value. Data represent the mean ± SEM of three independent
experiments performed each in triplicate. ⁄⁄⁄: Significantly different compared to FGF-2 treatment (P < 0.001) by one-way ANOVA followed by Dunnett’s comparison post-
test.
Fig. 4. (A) Correlation between mean BRET2max signal and mean ERK1/2 phosphor-
ylation levels after activation of FGFR1 with different FGF agonist ligand treatment.
Coefficient of determination R2 = 0.90. (B) Schematic representation of the evolu-
tionary tree of the FGF gene network adapted from [11] showing that the FGF
agonist ligands in each subfamily have similar characteristics with regard to their
ability to increase FGFR1 homodimerization and ERK1/2 phosphorylation. – no
effect, / and d low increase (between 0–25%), // and dd moderate increase
(between 25–5/0%), /// and ddd high increase (between 50–100%).
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produce FGFR1 homodimerization. Among the FGF ligands that
produce a significant increased in the BRET2 signal and ERK1/2
phosphorylation FGF-1, -2, 4, -5, -6 and -19. FGF-8, FGF-9 and
FGF-20 showed significantly reduced potencies vs FGF-2 in
addition to having a reduced efficacy vs FGF-2 as seen from the
BRET2max value.
Still another difference among the FGF agonist ligands was in
their temporal dynamics to produce and maintain the rise of their
BRET2max values. Again, FGF-9 and FGF-20 differed from FGF-2 and
also FGF-4 in failing to maintain their BRET2max values over the first
10 min period. Instead, a marked reduction of their maximal values
took place. This may reflect instability of the FGFR1 homodimers
formed upon activation with these two agonist ligands leading to
an increase in their dissociation rate. Taken together the various
FGF agonist ligands of the FGF family show substantial differences
in producing and maintaining FGFR1 homodimers in living cells,
which can help explain their differential biologic effects as illus-
trated here on the MAPK pathway.
A major result of this study is also that the FGF agonist ligands
belonging to the same subfamily of the FGF gene family [14] have
similar properties in terms of ability to produce and maintain
FGFR1 homodimers and to increase MAPK signaling. Thus, the evo-
lutionary relationship within this gene family appears to have a
distinct functional relevance.
Taken together, homodimerization of FGFR1 appear to be a fun-
damental mechanism for the agonist activity of all FGF ligands at
least in the case of the MAPK signaling.
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